Scholarlink

<p>Metastases represent one of the hardest obstacles in cancer treatment, accounting for many cancer-related deaths. Understanding the mechanisms that drive disease progression is essential to improve patient outcomes and develop more effective therapeutic strategies. This phenomenon appears to be elicited by dormant cancer cells (DCCs), which can persist undetected for extended periods of time, entering a non-proliferative, hibernation-like state that confers resistance to conventional therapies and facilitates immune evasion.</p><p>Owing to their status as a rare and energy-restricted population, combined with the limitations of current medical imaging, DCCs often evade early detection, hindering timely intervention and effective clinical management. Consequently, a critical need exists to develop high-resolution detection systems and identify specific DCC targetable biomarkers.</p><p>Here, a comprehensive overview of the current understanding of DCCs is reported, with a focus on recent advancements in experimental strategies for their identification and tracking, as well as therapeutic approaches currently under clinical investigation aimed at targeting these elusive cells.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Decoding cancer dormancy: integrative genomic, phenotypic and live-cell imaging analysis to reveal the hidden cancer cell reservoir

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月12日

查看全文
  • Gaetana Porcelli,
  • Caterina D’Accardo,
  • Francesca Angeloro,
  • Martina Cucchiara,
  • Paola Bianca,
  • Vincenzo Davide Pantina,
  • Narges Roozafzay,
  • Chiara Modica,
  • Miriam Gaggianesi,
  • Sebastiano Di Bella,
  • Giorgio Stassi,
  • Alice Turdo,
  • Matilde Todaro

摘要

Metastases represent one of the hardest obstacles in cancer treatment, accounting for many cancer-related deaths. Understanding the mechanisms that drive disease progression is essential to improve patient outcomes and develop more effective therapeutic strategies. This phenomenon appears to be elicited by dormant cancer cells (DCCs), which can persist undetected for extended periods of time, entering a non-proliferative, hibernation-like state that confers resistance to conventional therapies and facilitates immune evasion.

Owing to their status as a rare and energy-restricted population, combined with the limitations of current medical imaging, DCCs often evade early detection, hindering timely intervention and effective clinical management. Consequently, a critical need exists to develop high-resolution detection systems and identify specific DCC targetable biomarkers.

Here, a comprehensive overview of the current understanding of DCCs is reported, with a focus on recent advancements in experimental strategies for their identification and tracking, as well as therapeutic approaches currently under clinical investigation aimed at targeting these elusive cells.